AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 172 min read$ALKS

Nichols Christian Todd sold $373K of ALKS

Nichols Christian Todd (SVP, Chief Commercial Officer) sold 7,576 shares of Alkermes plc. (ALKS) at an average of $49.23 ($49.19–$49.65, $0.37M total) across 2 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Nichols Christian Todd
Published Aug 17, 2026, 10:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a senior commercial officer, pre-arranged under Rule 10b5-1, which typically reduces interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale, but there is no new fundamental information to drive a directional repricing.

03

What to watch

The filing does not state whether other insiders or the company itself made offsetting purchases, so the net insider signal is incomplete.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17, same day as the open-market sale trades

Background

The article is an SEC Form 4 insider transaction disclosure for Alkermes plc (ALKS).

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes disclosed via Form 4 that SVP Chief Commercial Officer Nichols Christian Todd sold 7,576 shares in open-market trades on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about signaling than fundamentals.

Evidence & confidence

The filing is an insider transaction with explicit 10b5-1 pre-arrangement, and the article provides no accompanying guidance, earnings, regulatory, or deal information.

Market effects

Sector

No clear sector read-through; this is company-specific insider selling without new sector/regulatory developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Alkermes plc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Nichols Christian Todd

    SVP, Chief Commercial Officer who sold shares.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan noted as Yes, indicating scheduled trading.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

AUG 28
$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

sleepreviewmag.com2 min
AUG 27
$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

simplywall.st2 min
AUG 25
$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.

finanznachrichten.de2 min